曲马多治疗糖尿病性神经病变疼痛的长期疗效维持。

文章的细节

引用

复制到剪贴板

Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblath D, Olson WH, Kamin M

曲马多治疗糖尿病性神经病变疼痛的长期疗效维持。

中华糖尿病杂志2000 03 - 04;14(2):65-70。

PubMed ID

10959067 (PubMed视图

］

摘要

目的:本研究的目的是评估曲马多在6周双盲随机试验后6个月的疗效和安全性。研究必威国际app设计和方法:完成双盲研究的疼痛性糖尿病神经病患者有资格参加长达6个月的开放扩展研究。所有患者均给予曲马多50 ~ 400 mg/d。自我疼痛强度评分(0-4级;无极度疼痛)和疼痛缓解评分(量表-1-4;更严重的完全缓解)记录在开放延长的第一天(双盲期的最后一天)，以及在30天，90天和180天。结果:共有117名患者(56名前曲马多和61名前安慰剂)进入研究。在研究的第一天，以前接受安慰剂治疗的患者的平均疼痛强度评分显著较高(2。2+/-1.02 vs. 1.4+/-0.93, P<0.001)和较低的疼痛缓解评分(0。9+/-1.43 vs. 2.2+/-1.27, P<0.001)。 By Day 90, both groups had mean pain intensity scores of 1.4, which were maintained throughout the study. Mean pain relief scores (2. 4+/-1.09 vs. 2.2+/-1.14) were similar after 30 days in the former placebo and former tramadol groups, respectively and were maintained for the duration of the study. Four patients discontinued therapy due to ineffective pain relief; 13 patients discontinued due to adverse events. The most common adverse events were constipation, nausea, and headache. CONCLUSIONS: Tramadol provides long-term relief of the pain of diabetic neuropathy.

引用本文的药物库数据

药物

曲马多